Could clearing lung bacteria boost cancer treatment?
NCT ID NCT05777603
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help treat advanced non-small cell lung cancer (NSCLC). The idea is that harmful bacteria in the lungs may help tumors grow, so clearing them might make the cancer treatment work better. About 23 adults with NSCLC that has returned or progressed will take the antibiotics at home for three 21-day cycles while receiving pembrolizumab at the clinic.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aerosolized aztreonam, aerosolized vancomycin, and pembrolizumab
What this could lead to
If it works, this could point toward a way to make standard cancer treatment more effective by also treating lung bacteria.
What could go wrong
This is a very early Phase 1 trial with only 23 people, so it is primarily testing safety and dosing. It may not improve outcomes, and the antibiotics can cause side effects like cough or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••